Indivior Pharmaceuticals Inc. (INDV) exhibits 80.2% gross margins and 62.2% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 13.4x enterprise multiple and 4.8% implied options volatility.
Sustained 80.2% gross profitability converts into 21.1% operating margin and 62.2% ROIC, outpacing sector cost of capital.
ROIC: 62.2% // GM: 80.2%YoY revenue trajectory of +4.3% paired with -2.24% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +4.3% // FCF YLD: -2.24%Altman Z-Score of 3.13 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.13 // F-SCORE: 5/9Trading at 19.8x trailing P/E (18.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 19.8x // EV/EBITDA: 13.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $35.37 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 16.9% net margins.
NET MARGIN: 16.9% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for INDV & activate live FRED threshold breach alerts.